Sector News

Pfizer to shutter vaccines sales business in China

April 2, 2015
Life sciences
(Reuters) – U.S. drugmaker Pfizer Inc said on Thursday it will cease its vaccines sales operations in China after an import license for one of its top-selling treatments, the only vaccine it sold in the country, was not renewed.
 
A Pfizer spokeswoman declined to say why the Chinese import license for Prevenar, an anti-bacterial treatment, had not been renewed. The China Food and Drug Administration regulatory agency could not immediately be reached for comment.
 
The move comes as drugmakers face growing difficulties obtaining approvals for medicines in China, the world’s No. 2 drug market, where pharmaceutical executives say over-stretched regulators have added more red tape to the process of bringing drugs to market.
  
“Based on a careful assessment of this situation, we have decided to cease our vaccines commercial operations in China at this time, effective immediately,” Pfizer spokeswoman Trupti Wagh said in comments emailed to Reuters.
 
Prevenar is the only vaccine Pfizer sells in China, and the move doesn’t affect its other operations in the country.
 
Strong growth in China sales of drugs including Prevenar helped Pfizer offset weaker global revenue growth last year.
 
Pfizer’s vaccines sales team has around 200 staff and “most colleagues will be impacted,” Wagh added. Pfizer has over 9,000 employees in China, according to its website, working in business segments including research and development, prescription drugs and consumer health products.
 
China’s fast-growing healthcare market is a magnet for global drugmakers, medical device firms and hospital operators, all keen to get a slice of a medical bill estimated to hit $1 trillion by 2020. Drug spending alone is set to hit $185 billion by 2018, according to IMS Health.
 
However, China’s drug approval backlog jumped a third last year, authorities said earlier this month, reflecting rising industry concern that it is getting harder to get medicines approved.
 
Wagh said Pfizer would work with Chinese regulators to bring Prevenar 13 – an updated version of the vaccine – to market at some point in future, although she added there was no clear time frame for this.
 
Pfizer’s global revenues from the Prevenar family of products, which includes Prevenar, was $4.5 billion last year, up 12 percent against 2013, the firm said in its annual report. This included “strong operational growth” in China.
 
Prevenar is used to help prevent pneumococcal disease, a bacterial infection which can lead to illnesses such as pneumonia, meningitis and sepsis, according to the National Foundation for Infectious Diseases. It is the only vaccine approved to treat children under two years old for the condition in China, Pfizer’s Wagh said.
 
The World Health Organization estimates there were around 14.5 million cases of serious pneumococcal disease in 2000, resulting in nearly 1 million deaths of young children.
 
By Adam Jourdan (Editing by Kenneth Maxwell)

Join the discussion!

Your email address will not be published. Required fields are marked *

Related News

January 23, 2021

Thermo Fisher Scientific acquires Novasep’s Henogen for $874.5m

Life sciences

Thermo Fisher Scientific has acquired Novasep’s viral vector manufacturing business in Belgium, Henogen, for about €725m ($874.5m) in cash. Henogen offers biotechnology firms, as well as biopharma customers contract manufacturing services for vaccines and therapies.

January 23, 2021

Lilly and Merus partner to develop T-Cell re-directing antibody therapies

Life sciences

Research and development group of Eli Lilly and Company, Loxo Oncology at Lilly, and clinical-stage oncology company Merus have announced a research collaboration and exclusive license agreement to develop T-Cell re-directing bispecific antibodies.

January 23, 2021

Adagene plans $125M IPO to go after cancer niches targeted by BMS and Pfizer

Life sciences

Chinese cancer biotech Adagene has filed to raise up to $125 million in a Nasdaq IPO. The listing will give Adagene the means to run early-phase clinical trials of antibodies against CD137 and CTLA-4.

Send this to a friend